Editorial Commentary
Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma
Abstract
Most head and neck squamous cell carcinoma (HNSCC) patients present with advanced-stage disease often with significant rates of local failure and distant metastases (1). Over the past two decades, the survival rates of HNSCC patients have not been altered significantly by standard therapy (2).
